Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.

Development Milestone

Drug Mechanism & Innovation Profile

• Molecular Architecture: Trispecific T-cell engager (TCE) with three distinct binding domains
• Target Strategy:
• CD19: Expressed on B cells throughout development
• BCMA: Highly expressed on plasma cells
• CD3: T-cell receptor component enabling T-cell engagement
• Therapeutic Rationale: Simultaneous targeting enables comprehensive depletion of both B-cell and plasma cell compartments
• Key Innovation: Potential to achieve durable immune system reset leading to drug-free remission
• Safety Advantage: Preclinical data showed extremely low levels of cytokine release, addressing a major safety concern with T-cell engagers

Preclinical Evidence

• Efficacy: Complete clearance of B cells and plasma cells demonstrated in preclinical models
• Safety: Extremely low cytokine release levels compared to conventional bispecific approaches
• Mechanistic Validation: Dual-targeting strategy (CD19 + BCMA) confirmed superior target coverage versus single-target approaches
• Therapeutic Window: Favorable safety profile supports clinical advancement in autoimmune indications

Strategic Partnership Framework

Licensing Agreement (November 2024)

• Parties: Leads Biolabs and Oblenio Bio (U.S.-based company founded with Aditum Bio)
• Scope: Exclusive global license for LBL-051
• Rights Granted: Development, manufacturing, and commercialization worldwide
• Strategic Rationale: Leverages Oblenio Bio’s expertise in autoimmune disease development and global regulatory pathways

Partnership Benefits

• Risk Sharing: Development costs and regulatory risks distributed across partners
• Global Reach: Immediate access to international markets through U.S.-based entity
• Expertise Alignment: Combines Leads Biolabs’ innovative platform with Oblenio Bio’s autoimmune disease focus
• Capital Efficiency: Enables Leads Biolabs to advance multiple pipeline assets simultaneously

Market Opportunity & Competitive Landscape

• Autoimmune Disease Burden: Refractory autoimmune conditions represent significant unmet medical need with limited treatment options
• Current Standard: Immunosuppressive therapies with chronic administration requirements and significant side effects
• Competitive Advantage: First-in-class trispecific approach offers potential for curative-like outcomes
• Market Potential: Drug-free remission represents paradigm shift with premium pricing potential
• Therapeutic Breadth: Platform applicable across multiple autoimmune indications (lupus, rheumatoid arthritis, etc.)

Forward Development Strategy

• Phase Ia Focus: Safety, tolerability, and preliminary efficacy in refractory autoimmune patients
• Dose Escalation: Careful assessment of cytokine release syndrome risk despite favorable preclinical profile
• Biomarker Strategy: Comprehensive immune monitoring to validate mechanism of action
• Next Milestones: Phase Ib/II expansion studies expected upon successful Phase Ia completion
• Regulatory Pathway: Potential for breakthrough therapy designation given high unmet need

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial progress, partnership benefits, and commercial potential. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, competitive dynamics, and partnership execution.-Fineline Info & Tech